Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03464487
Other study ID # Daily vs Intermittent LGIT
Secondary ID
Status Recruiting
Phase N/A
First received January 1, 2018
Last updated March 7, 2018
Start date February 15, 2018
Est. completion date January 2019

Study information

Verified date March 2018
Source All India Institute of Medical Sciences, New Delhi
Contact Sheffali Gulati, M.D.
Phone 26594679
Email sheffaligulati@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Drug resistant epilepsy constitutes about one third of all children diagnosed with epilepsy. Although ketogenic diet is being used for drug resistant epilepsy for almost hundred years, its restrictiveness and adverse effects interferes with its compliance. So less restrictive alternatives like Low Glycemic Index Therapy diet is gradually becoming more popular and its effectiveness is well established. Still the restrictiveness of such monotonous diets is one of the most significant issues for long term maintenance of children on dietary therapy. In this study, we are planning to compare the efficacy of daily and intermittent Low Glycemic Index therapy Diet in children aged 1-15 years with drug resistant epilepsy in a open labelled randomized controlled non-inferiority trial. The children in intermittent LGIT arm will receive the dietary therapy for five days of each week, alternating with a liberal diet on the rest of the two days of the week.


Description:

Drug resistant epilepsy constitutes about one third of all children diagnosed with epilepsy. Although ketogenic diet is being used for drug resistant epilepsy for almost hundred years, its restrictiveness and adverse effects interferes with its compliance. So less restrictive alternatives like Low Glycemic Index Therapy diet is gradually becoming more popular and its effectiveness is well established. Still the restrictiveness of such monotonous diets is one of the most significant issues for long term maintenance of children on dietary therapy. In this study, we are planning to compare the efficacy of daily and intermittent Low Glycemic Index therapy Diet in children aged 1-15 years with drug resistant epilepsy in a open labelled randomized controlled non-inferiority trial. The children in intermittent LGIT arm will receive the dietary therapy for five days of each week, alternating with a liberal diet on the rest of the two days of the week. With a follow up period of 6 months, we are planning to enroll 55 children in each arm. Adverse effect profile in each arm will also be monitored during the study. Also the effect of the dietary therapy on behavior and cognition in each arm will be assessed.


Recruitment information / eligibility

Status Recruiting
Enrollment 110
Est. completion date January 2019
Est. primary completion date January 2019
Accepts healthy volunteers No
Gender All
Age group 1 Year to 15 Years
Eligibility Inclusion Criteria:

1. Children aged 1-15 years with drug resistant epilepsy

2. Willing to come for regular follow up

Exclusion Criteria:

1. Surgically remediable cause for drug resistant epilepsy

2. Proven in born error of metabolism except in which dietary therapy for epilepsy is indicated(i.e. pyruvate carboxylase deficiency and GLUT 1 deficiency)

3. Previously received KD, MAD or LGIT

4. Known case of

- Chronic kidney disease

- Chronic liver disease/GI illness

- Chronic heart disease(congenital and acquired)

- Chronic respiratory illness

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Low Glycemic Index Therapy Diet
Low Glycemic Index Therapy Diet allows only carbohydrates with Glycemic Index less than 50 and also restricts daily carbohydrate intake to less than 40-60 gram per day.

Locations

Country Name City State
India AIIMS New Delhi Delhi

Sponsors (1)

Lead Sponsor Collaborator
All India Institute of Medical Sciences, New Delhi

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of seizure reduction from baseline at 24 weeks in each arm Percentage of seizure reduction from baseline at 24 weeks in each arm will be calculated from Daily Seizure Log maintained by parents Percentage of seizure reduction at 24 weeks=x-y/x X 100 Y=Mean daily seizures at 24 weeks as measured over past 4 weeks X=Mean daily seizures at baseline as measured over 4 weeks Seizure log will contain details of number, duration and type of seizures as recorded by parents Percentage seizure reduction will be calculated for each child in each arm after 24 weeks follow up period is completed and finally mean seizure reduction in each arm will be computed at the end of 24 weeks
Secondary Proportion of patients with >50% seizure reduction in each dietary arm Proportion of patients with >50% seizure reduction in each dietary arm will be computed from daily seizure log maintained by parents At the end of 24 weeks, it will be determined the proportion of children in each arm with >50% reduction in seizure frequency.
Secondary Change in social quotient with each dietary therapy Proportion of children with improvement in social quotient at 24 weeks as compared to baseline measured by Vineland Social Maturity scale Vineland Social Maturity Scale will be done for each child at baseline and at 24 weeks to calculate social quotient at baseline and 24 weeks
Secondary Proportion of patients with different clinical adverse events in each group Each participant will be monitored clinically for adverse effects like nausea, vomiting, constipation Each child will be monitored for adverse effects clinically at 12 weeks and 24 weeks
Secondary Correlate seizure frequency change at 24 weeks with blood HbA1c levels Absolute level of blood HbA1c(in percentage) as compared to percentage change in seizure frequency at 3 and 6 months will be computed Absolute level of HbA1c levels (in percentage) as compared to percentage change in seizure frequency at 3 and 6 months will be computed
Secondary Correlate seizure frequency change at 24 weeks with blood betahydroxy butyrate levels levels Blood beta hydroxyl butyrate levels(milimoles/liter) at 12 and 24 weeks as compared to percentage change in seizure frequency will be computed Blood beta hydroxyl butyrate levels(milimoles/liter) at 12 and 24 weeks as compared to percentage change in seizure frequency will be computed
Secondary Proportion of patients with different biochemical adverse events in each group Each participant will be monitored for side effects like anemia, dyslipidemia, deranged liver and renal function tests Each child will be monitored by certain biochemical investigations like hemoglobin, liver and renal function tests and lipid profile at baseline, at 24 weeks and also in between if clinically indicated
See also
  Status Clinical Trial Phase
Completed NCT04378075 - A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy Phase 2/Phase 3
Recruiting NCT05928598 - Goals for Epilepsy Clinic Visits Trial N/A
Recruiting NCT05539287 - Clinical Study Evaluating the Safety of Lactobacillus Probiotic in Children With Drug Resistant Epilepsy Phase 2
Not yet recruiting NCT04601974 - Lentiviral Gene Therapy for Epilepsy Phase 1/Phase 2
Completed NCT02982824 - Effect of Magnesium Supplementation for Children With Drug Resistant Idiopathic Epilepsy N/A
Recruiting NCT05485558 - the Safety and Efficacy of N-acetyl Cysteine in Children With Drug-Resistant Epilepsy Phase 2
Not yet recruiting NCT04553354 - Cortical Resections in Drug Resistant Epilepsy
Recruiting NCT04999046 - NaviFUS™ System Neuromodulating Treatment for Patients With Drug Resistant Epilepsy N/A
Recruiting NCT04714996 - Efficacy, Safety and Pharmacokinetics of ES-481 in Adult Patients With Drug Resistant Epilepsy Phase 2
Recruiting NCT04839601 - RNS System RESPONSE Study N/A
Recruiting NCT06059157 - Epileptogenic Network Visualisation With Advanced MRI N/A
Recruiting NCT05947656 - Evaluation of the NaviFUS System in Drug Resistant Epilepsy N/A
Recruiting NCT05393518 - Electroclinical Correlation of Anxiety N/A
Not yet recruiting NCT05555537 - MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy
Completed NCT03419000 - Circulating microRNAs as Biomarkers of RESPIratory Dysfunction in Patients With Refractory epilePSY N/A
Enrolling by invitation NCT06341075 - Real-World Study of Magnetic Resonance-guided Laser Interstitial Thermal Therapy for Drug-resistant Epilepsy N/A
Not yet recruiting NCT05527093 - Cartography of Social Cognition Network and Their Alterations in Patients With Epilepsy N/A
Recruiting NCT05697614 - The Benefit and Safety of Older Generation Anti-Epileptic Drugs (AEDs) in Drug-Resistant Epilepsy Children Phase 4
Recruiting NCT06309251 - Effectiveness and Impact on the Quality of Life of Ketogenic Diet in Pediatric Patients
Recruiting NCT06432907 - StereoEEG Motor Neuronal Potentials Decoding N/A